CD8A and graft versus host disease: As for CD8+ T cells alone, CD3+ allo-TCXCR4 showed greater antitumor activity than control cells (Figure 7E; median survival 43 days vs. 38 days, P = 0.01 by log-rank Mantel-Cox test), but this was not associated with increased GVHD severity as evidenced by equivalent weight loss in BMT recipients of allo-TCXCR4 and allo-TControl, and no increase in histological GVHD (Figure 7F).